ProfileGDS5678 / 1447960_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 20% 17% 17% 17% 17% 17% 17% 17% 17% 17% 17% 17% 19% 17% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4940220
GSM967853U87-EV human glioblastoma xenograft - Control 22.4227917
GSM967854U87-EV human glioblastoma xenograft - Control 32.4230217
GSM967855U87-EV human glioblastoma xenograft - Control 42.3604117
GSM967856U87-EV human glioblastoma xenograft - Control 52.3587117
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.4812717
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4351517
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.3940817
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.3919317
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4123817
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.409917
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.3802717
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4472919
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4124417